Deep Medicine Acquisition (Deep Medicine Acquisition) Debt-to-Equity : -2.41 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Debt-to-Equity?

Deep Medicine Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.15 Mil. Deep Medicine Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Deep Medicine Acquisition's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-0.89 Mil. Deep Medicine Acquisition's debt to equity for the quarter that ended in Sep. 2023 was -2.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Deep Medicine Acquisition's Debt-to-Equity or its related term are showing as below:

DMAQ' s Debt-to-Equity Range Over the Past 10 Years
Min: -55.56 Med: 0 Max: 0.9
Current: -2.41

During the past 3 years, the highest Debt-to-Equity Ratio of Deep Medicine Acquisition was 0.90. The lowest was -55.56. And the median was 0.00.

DMAQ's Debt-to-Equity is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.12 vs DMAQ: -2.41

Deep Medicine Acquisition Debt-to-Equity Historical Data

The historical data trend for Deep Medicine Acquisition's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Debt-to-Equity Chart

Deep Medicine Acquisition Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Equity

-55.56

0.73

Deep Medicine Acquisition Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial							-	0.55	0.73	0.90	-2.41

Competitive Comparison of Deep Medicine Acquisition's Debt-to-Equity

For the Shell Companies subindustry, Deep Medicine Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deep Medicine Acquisition's Debt-to-Equity Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's Debt-to-Equity falls into.

Deep Medicine Acquisition Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Deep Medicine Acquisition's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.865	+	0)	/	2.554
	=	0.73

Deep Medicine Acquisition's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.15	+	0)	/	-0.892
	=	-2.41

Deep Medicine Acquisition (NAS:DMAQ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Deep Medicine Acquisition Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Madison Avenue, 12th Floor, New York, NY, USA, 10017

Website

Deep Medicine Acquisition Corp is a blank check company.

Executives

John Chiang	director	3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen	director, officer: Chief Executive Officer	C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo	officer: Chief Financial Officer	40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc	10 percent owner	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017